Keybanc analyst Brandon Nispel downgrades Crown Castle (NYSE:CCI) from Overweight to Sector Weight.
SVB Leerink Maintains Outperform on AlloVir, Lowers Price Target to $37
SVB Leerink analyst Mani Foroohar maintains AlloVir (NASDAQ:ALVR) with a Outperform and lowers the price target from $41 to $37.